BiotechTube

Empagliflozin + DPP-4 inhibitor + GLP-1 receptor agonist

Pre-clinicalActive
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2

Trial Timeline

Oct 16, 2017 → Apr 30, 2026

NCT ID
NCT03363464

About Empagliflozin + DPP-4 inhibitor + GLP-1 receptor agonist

Empagliflozin + DPP-4 inhibitor + GLP-1 receptor agonist is a pre-clinical stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is active. This product is registered under clinical trial identifier NCT03363464. Target conditions include Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT03363464Pre-clinicalActive

Competing Products

20 competing products in Diabetes Mellitus, Type 2

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85